Sino Biopharm (1177.HK) Announces 2025 Annual Results
– Innovation and R&D Advance Steadily, RMB 31.83 Billion in Revenue Recorded – Underlying Profit Attributable to Owners of the Parent of RMB 4.54 Billion Recorded Development Highlights – During…
Sino Biopharm (1177.HK) Announces 2025 Interim Results
– Sales of Innovative Products Up by 27.2% Year-on-Year to RMB7.8 Billion – Profit Attributable to Owners of the Parent from Continuing Operations Surges 140.2% – Continues R&D Investment Speeds…
Sino Biopharm (1177.HK) Announces 2024 Annual Results
– Dual Success of Innovative Drugs and Generic Drugs – Revenue Recorded RMB28.87 Billion – Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Recorded RMB3.46 Billion Financial Highlights…
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
– Innovative R&D Yields Fruitful Results Once Again, Revenue Rises to RMB6.13 Billion – Adjusted Non-HKFRS Profit Attributable to the Owners of the Parent up 14.0% – New Products Boost…
Sino Biopharm (1177.HK) Announces 2023 Annual Results
Innovative Products Continued to Deliver and Perform Excellently Revenue Recorded RMB26.20 Billion Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Recorded RMB2.59 Billion Sino Biopharmaceutical Limited (Sino Biopharm…
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
Contribution of Sales of New Products to Revenue Rises to 47.4% Driving Revenue Up by 16.4% Sino Biopharmaceutical Limited (Sino Biopharmaceutical or the Company, together with its subsidiaries, the Group)…
Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity
By Accelerating New Drug Development and Employing New Online Platforms Sales of New Drugs Marketed over Past Three Years Double to RMB8.06 Billion Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the…
Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China
Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Group”; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., Ltd. (“Sinovac LS”, previously known as Sinovac Research…
Sino Biopharm Announces 2020 Interim Results
Revenue Increases by 1.0% to RMB12.648 Billion Underlying Profit up 5.2% to RMB1.761 Billion Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a…
Sino Biopharmaceutical Announces 2019 Third Quarterly Results
Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly…
Sino Biopharmaceutical Announces 2019 First Quarterly Results
Revenue Up 33.4% to RMB6,208 Million Underlying Profit* Climbs 22.4% to RMB976 Million Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading…
Sino Biopharmaceutical’s 2018 Annual Results Reaches New Height
Revenue Up 41% to RMB20.9 Billion and Net Profit Climbs 317% to RMB9 Billion HONG KONG – (ACN Newswire) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with…